AbbVie Outlines Growth in SKYRIZI, RINVOQ and Pipeline Advances at Wells Fargo Conference
At the Wells Fargo conference, AbbVie highlighted continued growth for its key products SKYRIZI and RINVOQ across immunology markets such as inflammatory bowel disease, vitiligo, alopecia, and hidradenitis suppurativa. The company expects a subcutaneous induction regimen of SKYRIZI to gain approval in the fourth quarter for Crohn's disease, supported by strong endoscopic healing results from its AFFIRM study. AbbVie is also advancing combination therapies that show improved outcomes compared to monotherapy and plans additional data releases later this year. In oncology, early-stage BCMA-directed therapy etentamig demonstrated promising multiple myeloma results and could lead to a regulatory filing soon. The company remains focused on strategic acquisitions and partnerships while increasing R&D spending toward $10 billion annually. Management reaffirmed its outlook for high-single-digit annual revenue growth through the decade, emphasizing long-term opportunities in immunology, oncology, and neuroscience.
Topics: AbbVie business development drug pipeline RINVOQ SKYRIZI